High-dose chemotherapy in adult acute myeloid leukemia: Rationale and results
- 31 July 1996
- journal article
- review article
- Published by Elsevier in Leukemia Research
- Vol. 20 (7) , 535-549
- https://doi.org/10.1016/0145-2126(96)00016-1
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia clinical results in 46 patientsCancer, 1993
- Treatment of the Newly Diagnosed Adult with De Noyo Acute Myeloid LeukemiaHematology/Oncology Clinics of North America, 1993
- Treatment of Relapsed or Refractory AML with Intermediate-dose Arabinosylcytosine (Ara-C): Confirmation of the Importance of Ara-C Triphosphate Formation in Mediating Response to Ara-CLeukemia & Lymphoma, 1993
- Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia.Journal of Clinical Oncology, 1992
- A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group BBlood, 1991
- Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study GroupBlood, 1990
- HOW CAN WE CURE LEUKAEMIA?British Journal of Haematology, 1989
- High-dose cytosine arabinoside therapy for refractory leukemiaBlood, 1983
- Treatment of acute myelocytic leukemia: a study by cancer and leukemia group BBlood, 1981
- High dose cytosine arabinoside (HDARAC) in refractory acute leukemiaCancer, 1979